민주홍 (성균관대학교 의과대학)님 | 한빛사연구자 > 한빛사

성균관대학교 의과대학

최종업데이트 2026.02.19.

Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- JAMA Netw. Open, Feb 02 2026, 9 (2) e2559471 | https://doi.org/10.1001/jamanetworkopen.2025.59471
- 2026-02
- 의약학
- 한빛사논문
Risk of Parkinson's disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea
- J. Neurol. Neurosurg. Psychiatry, 2022 Jul 28;jnnp-2022-329389. | http://dx.doi.org/10.1136/jnnp-2022-329389
- 2022-07
- 의약학
- 한빛사논문
Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea
- J. Neurol. Neurosurg. Psychiatry, 2022 Aug 26;jnnp-2022-329628. | doi: 10.1136/jnnp-2022-329628
- 2022-08
- 의약학
- 한빛사논문
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
- Mult. Scler. J., January 2012 vol. 18 no. 1 113-115 | doi: 10.1177/1352458511431973
- 2012-01
- 의약학
- 상위피인용논문

연구자 ID

저자논문